Palo Alto Investors »

Vyne Therapeutics shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.0M 445k 2.33

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical (BMRN)
Biogen Idec (BIIB)
United Therapeutics Corporation (UTHR)
ACADIA Pharmaceuticals (ACAD)
Prothena Corp SHS (PRTA)
Revance Therapeutics (RVNC)
Staar Surgical Com Par $0.01 (STAA)
Alnylam Pharmaceuticals (ALNY)
eHealth (EHTH)
Sage Therapeutics (SAGE)
Sarepta Therapeutics (SRPT)
Iovance Biotherapeutics (IOVA)
Alkermes SHS (ALKS)

View all positions for Palo Alto Investors

Top funds holding Vyne Therapeutics

Cormorant Asset Management
Eventide Asset Management
Citadel Advisors
Soleus Capital Management
DSC Advisors
Palo Alto Investors
AlphaCentric Advisors
Exome Asset Management
Fred Alger Management
Vanguard Group
Millennium Management
Hrt Financial
Us Bancorp
Bank of America Corporation
Royal Bank of Canada

View all funds holding Vyne Therapeutics